Announcement

Collapse
No announcement yet.

Successes and Failures of Stem Cell Transplantation in Autoimmune Diseases

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Successes and Failures of Stem Cell Transplantation in Autoimmune Diseases

    This was published in 2011, following a more detailed report released in 2009. - Dave

    Successes and Failures of Stem Cell Transplantation in Autoimmune Diseases

    Alan Tyndall
    + Author Affiliations

    1University of Basel, Basel, Switzerland

    Abstract

    Over the past 15 years, more than 1500 patients have received HSCT, mostly autologous, as treatment for a severe autoimmune disease (AD). More than 1000 of these have been registered in the European Group for Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) combined database. A recent retrospective analysis of 900 patients showed that the majority had multiple sclerosis (MS; n = 345) followed by systemic sclerosis (SSc; n = 175), systemic lupus erythematosus (SLE; n = 85), rheumatoid arthritis (RA; n = 89), juvenile idiopathic arthritis (JIA; n = 65), and idiopathic cytopenic purpura (ITP; n = 37). An overall 85% 5-year survival and 43% progression-free survival was seen, with 100-day transplantation-related mortality (TRM) ranging between 1% (RA) and 11% (SLE and JIA). Approximately 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many patients, such as in those with SSc, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented beyond any predicted known effects of intense immunosuppression alone. The high TRM was in part related to conditioning intensity, comorbidity, and age, but until the results of the 3 prospective randomized trials are known, an evidence-based modification of the conditioning regimen will not be possible.1 In recent years, multipotent mesenchymal stromal cells (MSCs) have been tested in various AD, exploiting their immune-modulating properties and apparent low acute toxicity. Despite encouraging small phase 1/2 studies, no positive data from randomized, prospective studies are as yet available in the peer-reviewed literature.

    Full Text: http://asheducationbook.hematologyli...011/1/280.full

    2009 Article:
    http://www.haematologica.org/content/95/2/284.full#T4
    Dave Bexfield
    ActiveMSers
Working...
X